Dolomite, a manufacturer of microfluidic systems and devices, has developed a novel droplet merger chip with GigaGen of San Francisco, CA for massively parallel single cell genetic analysis.
Measuring 15mm x 22.5mm, the glass microfluidic chip facilitates fast and consistent merging of two individual droplet streams, benefiting a range of applications including DNA amplification, biochemical analysis, single cell analysis and high throughput experimentation. Unlike other methods, which incorporate expensive and bulky high voltage electronics to merge droplets using electrostatic forces, the droplet merger chip works by simply “squeezing” droplets together in a carefully designed merging chamber.
Dolomite says the result is a unique microfluidic device, which points the way to low cost disposable chips in future versions.
‘A simple and reliable droplet merging technology is an important step forward for us,’ said David Johnson, chief executive and founder of GigaGen. ‘We are now using these chips in our system for massively parallel single cell genetic analysis.’
GigaGen has filed a patent application describing the chip design and its applications in the field of genetic analysis of cells.
As part of a licensing agreement with GigaGen, Dolomite will be offering the technology later this year to researchers in academia and commercial users in a wide range of application areas.
‘Many of our customers have asked us for chips to create droplets, merge them, and then carry out further processing and analysis,’ said Andrew Lovatt, chief executive of Dolomite.
‘Our partnership with Sphere Fluidics gives us additional capability in selecting the surfactants we use, to optimise droplet behaviour and stability under a wide range of temperature and biological conditions.’
Dolomite and GigaGen develop droplet merging technology
For use in massively parallel single cell genetic analysis
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Dolomite and Lab on a Chip launch Productizing Science Competition 2015
Dolomite and Lab on a Chip are challenging entrepreneurial researchers, scientists and engineers to enter the Productizing Science Competition 2015, proposing novel, microfluidics-based concepts with commercial potential
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
PhoreMost announces PMC-001 as lead oncology programme
The biotech will advance the small molecule towards Phase I trials, positioning it for the treatment of primary and secondary brain cancers. Dr Gabriel Fox will also join the company as Consulting Chief Medical Officer to lead the clinical development of the molecule
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza